Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 30;14(7):1746–1759. doi: 10.1080/21645515.2017.1423154

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Crown copyright

PMC Copyright notice

Figure 6. — Immunogenicity of SLA/LA-OVA. C57BL/6 mice (n = 10/group) were injected i.m. on Days 0 and 21 with PBS, ovalbumin (20 µg) or OVA-SLA/LA (20 µg; based on antigen dose). Animals were bled on Day 35 and serum analyzed for anti-OVA IgG Abs by ELISA (Panel A; group geometric means ± standard deviation). In addition, the levels of OVA-specific CD8⁺ cells were assessed by tetramer analysis in the whole blood of mice collected on Day 28 (Panel B; group means ± standard deviation). Mouse survival was tracked after tumor challenge with of 10⁶ B16-ova cells on Day 50 (Panel C). **** represents p <0.0001.